XM does not provide services to residents of the United States of America.
D
D

DentsplySirona

Trade Ideas

Traders Sentiment

Technical Summary

Hourly

News

U.S. earnings week ahead

DIARY-U.S. earnings week ahead Feb 23 (Reuters) - Diary of U.S. (.SPX) corporate earnings for the week ahead. ** Please Note - All times given are in U.S. EDT unless otherwise stated ** U.S. EARNINGS Start Date Start Time RIC Company Name Event Name 26-Feb-2024 AMC PGR Progressive Corp Q4 2023 Progressive Corp Earnings Release 26-Feb-2024 AMC SBAC.O SBA Communications Corp Q4 2023 SBA Communications Corp Earnings Release 26-Feb-2024 AMC OKE ONEOK Inc Q4 2023 ONEOK Inc Earnings Release 26-Feb-202
A
A
E
M
N
S
D
U
C
P
U

Dentsply Sirona, A-dec Expand Collaboration By Integrating Primescan Connect Into A-dec Delivery Systems

BRIEF-Dentsply Sirona, A-dec Expand Collaboration By Integrating Primescan Connect Into A-dec Delivery Systems Feb 21 (Reuters) - DENTSPLY SIRONA Inc XRAY.O : DENTSPLY SIRONA INC - CO, A-DEC EXPAND THEIR COLLABORATION BY INTEGRATING PRIMESCAN CONNECT INTO A-DEC DELIVERY SYSTEMS Source text for Eikon: [ID:] Further company coverage: XRAY.O
D

U.S. Biomarin Pharmaceutical, Cisco, Microsoft

U.S. RESEARCH ROUNDUP-Biomarin Pharmaceutical, Cisco, Microsoft Nov 16 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Biomarin Pharmaceutical, Cisco, and Microsoft, on Thursday. HIGHLIGHTS * Biomarin Pharmaceutical BMRN.O : Wells Fargo initiates coverage with overweight rating * Cisco CSCO.O : Evercore ISI cuts target price to $55 from $63 * Deckers Brands DECK.N : Piper Sandler cuts to neutral from overweight * Hil
B
C
F
G
H
M
N
D
A
B
C
E

Dentsply Sirona Authorizes Additional $1 Bln Share Repurchase Program

BRIEF-Dentsply Sirona Authorizes Additional $1 Bln Share Repurchase Program Nov 9 (Reuters) - DENTSPLY SIRONA Inc XRAY.O : DENTSPLY SIRONA INC - WILL INTRODUCE THREE-YEAR FINANCIAL TARGETS INCLUDING DETAILS OF ITS PLAN TO ACHIEVE ADJUSTED EPS OF $3.00 IN 2026 DENTSPLY SIRONA INC - BOARD OF DIRECTORS HAS AUTHORIZED AN ADDITIONAL $1 BILLION SHARE REPURCHASE PROGRAM DENTSPLY SIRONA- DOUBLE-DIGIT ADJUSTED.
D

S&P 500 top and bottom performing stocks at about 03:30 p.m. EDT

BUZZ - S&P 500 top and bottom performing stocks at about 03:30 p.m. EDT S&P 500 .SPX Top Performers Percent Change VF Corp VFC.N +11.9% Teleflex Inc TFX.N +10.9% Tyler Technologies Inc TYL.N +10.4% Paramount Global PARA.OQ +10.2% Parker-Hannifin Corp PH.N +10.2% Bottom Performers Percent Change Borgwarner Inc BWA.N -12.9% Aptiv PLC APTV.N -10.4% Mo
D
U
A
B
P
T

Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.